Seagen to host conference call and webcast discussion on september 21, 2021 to discuss tivdak™ (tisotumab vedotin-tftv) approval

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) will host a conference call and webcast on tuesday, september 21, 2021 to discuss the u.s. food and drug administration approval of tivdak™ (tisotumab vedotin-tftv). access to the event can be obtained as follows: september 21, 2021 6:00 a.m. pacific time / 9:00 a.m. eastern time telephone 844-763-8274 (u.s.) or +1 412-717-9224 (international); conference id 10160278 webcast with slides will be available at www.seagen.com in the invest
SGEN Ratings Summary
SGEN Quant Ranking